We recently published 10 Stocks Hit by Painful Plunge. Novo Nordisk A/S (NYSE:NVO) is one of the best-performing stocks on ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...

Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

The Fed kept rates steady, as most economists had expected, but struck a more hawkish tone, causing a mid-afternoon stock sell-off.

The persistent threat of reciprocal tariffs from US President Donald Trump has resulted in many trade deals, while the IMF ...

David Ellison has finally sealed his $8bn takeover of Paramount, but only after a year of boardroom battles and bloodletting ...

Investors braced for the Federal Reserve's next interest rate decision and earnings from tech giants Microsoft and Meta.

WEIGHT loss jabs could raise the risk of sudden blindness, a study warns. Injections like Wegovy, Mounjaro and Ozempic are ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Shares of telehealth company Hims & Hers Health are up Thursday afternoon. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market.